Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis.

about

Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis.

Item

http://www.wikidata.org/entity/Q45138053

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis.

@en

Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis.

@nl

type

Item

label

Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis.

@en

Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis.

@nl

prefLabel

Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis.

@en

Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis.

@nl

P1476

Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis

@en

P2093

Betti Schaefer

http://www.w3.org/2001/XMLSchema#string

Claus Peter Schmitt

http://www.w3.org/2001/XMLSchema#string

Elke Wühl

http://www.w3.org/2001/XMLSchema#string

Franz Schaefer

http://www.w3.org/2001/XMLSchema#string

Rüdiger Waldherr

http://www.w3.org/2001/XMLSchema#string

P2860

EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Clinical features and outcome of pediatric Wegener's granulomatosis.

New pathophysiological insights and treatment of ANCA-associated vasculitis.

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.

Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab.

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Clinical features in 17 paediatric patients with Wegener granulomatosis.

Biologic therapy in primary systemic vasculitis of the young.

Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy.

P2888

s00467-012-2332-4

P304

511-514

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00467-012-2332-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michal Malina

P577

2012-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1012671785

http://www.w3.org/2001/XMLSchema#string

P698

23124537

http://www.w3.org/2001/XMLSchema#string